New targeted therapies in Non-Small Cell Lung Cancer improve patient outcomes

Impact: Health and wellbeing, Economic


Lung cancer is the commonest cause of cancer-related mortality worldwide. Our research has driven pivotal trials leading to international licensing and routine clinical use globally of two new therapies, benefitting thousands of non-small cell lung cancer (NSCLC) patients worldwide and improving average survival from one year to four years. Osimertinib is licensed by the European Medicines Agency (EMA), the US Food and Drug Administration (FDA) and the Japanese Ministry of Health, Labour and Welfare (MHLW), recommended in European and US clinical guidance and available in >80 countries for treatment of epidermal growth factor receptor positive (EGFR+) NSCLC. Crizotinib is licensed by EMA and FDA, recommended in European and US clinical guidance and approved in >90 countries for treatment of anaplastic lymphoma kinase positive (ALK+) NSCLC.
Impact date1 Aug 201331 Dec 2020
Category of impactHealth and wellbeing, Economic
Impact levelAdoption

Research Beacons, Institutes and Platforms

  • Cancer
  • Manchester Cancer Research Centre